Dyadic International (NASDAQ:DYAI – Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01), Zacks reports. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. During the same quarter last year, the business earned ($0.07) earnings per share.
Dyadic International Price Performance
DYAI stock traded down $0.09 during mid-day trading on Thursday, reaching $1.27. 136,959 shares of the company’s stock were exchanged, compared to its average volume of 57,130. The company has a market cap of $37.13 million, a price-to-earnings ratio of -4.53 and a beta of 0.73. Dyadic International has a 12-month low of $1.13 and a 12-month high of $2.67. The stock’s 50 day moving average is $1.56 and its 200 day moving average is $1.58. The company has a debt-to-equity ratio of 1.29, a current ratio of 5.54 and a quick ratio of 5.54.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a research note on Monday, July 8th.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Read More
- Five stocks we like better than Dyadic International
- Top Biotech Stocks: Exploring Innovation Opportunities
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Where to Find Earnings Call Transcripts
- Jeff Brown’s Exegesis AI Stock Picks
- What is an Earnings Surprise?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.